Philips eyes expanded approval for digital imaging system for cancer

Philips ($PHG) is submitting positive study results for its digital imaging system for cancer to the FDA. The data could help the company get expanded approvals for its device in the U.S.

The controlled, multicenter pivotal validation study pitted Philips' digital whole slide imaging system against traditional microscope diagnoses. Researchers found that the study met its endpoint because the imaging device could provide a diagnosis as well as a microscope.

"Proving that digital reads are not inferior to optical reads creates a foundation for a FDA submission that, if cleared, would allow for the shift to a digital operation that, in turn, may reap the additional benefits of collaboration, workflow efficiency and the use of precise tools for measurement and counting," Dr. Michael Feldman, a professor of pathology at the Hospital of the University of Pennsylvania and a leader on the study, said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The study included 16 pathologists at four sites in the U.S. Researchers carried out 16,000 reads across 2,000 cases.

Philips’ device is already approved in the U.S. to help doctors diagnose a certain kind of breast cancer. The latest data backs a bid by the company to get the system approved for additional indications through a de novo submission.


Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.